Study guide
12.3 Viral Exanthems, Communicable Diseases & Pediatric Sepsis Management
Pediatric Nursing Certification PED-BC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, Blueprint & Clinical Decision-Making
1.1 ANCC PED-BC Exam Facts, Scoring & Test Blueprint 1.2 The Pediatric Nursing Process & Clinical Judgment Model 1.3 Prioritization, Clinical Case Analysis & Practice Strategies
2 Chapter 2: Pediatric Growth, Development & Milestones
2.1 Infancy and Toddlerhood: Physical Growth & Motor Milestones 2.2 Preschool, School-Age & Adolescent Milestones 2.3 Developmental Theories: Erikson, Piaget, Kohlberg & Freud
3 Chapter 3: Pediatric Physical Assessment, Vital Signs & Diagnostic Screening
3.1 Pediatric Physical Examination & Age-Specific Vital Sign Norms 3.2 Pediatric Pain Assessment Scales & Developmental Screening 3.3 Pediatric Laboratory Values & Diagnostic Specimen Collection
4 Chapter 4: Pediatric Fluid, Electrolyte & Nutritional Management
4.1 Dehydration Severity, Oral Rehydration Therapy & IV Deficit Replacement 4.2 Pediatric Electrolyte Disturbances: Sodium, Potassium & Calcium Imbalances 4.3 Infant Nutrition, Formula Preparation, Failure to Thrive & Deficiencies
5 Chapter 5: Pediatric Respiratory Emergencies & Chronic Pulmonary Conditions
5.1 Upper Airway Obstruction: Croup, Epiglottitis & Foreign Body Aspiration 5.2 Lower Airway Infections: Bronchiolitis (RSV) & Pediatric Pneumonia 5.3 Chronic Pulmonary Disorders: Pediatric Asthma & Cystic Fibrosis Management
6 Chapter 6: Pediatric Congenital & Acquired Cardiovascular Disorders
6.1 Acyanotic Congenital Heart Defects: Left-to-Right Shunts & Obstructive Lesions 6.2 Cyanotic Defects & Complex Anomalies: Tetralogy of Fallot, TGA & Hypercyanotic Spells 6.3 Acquired Pediatric Heart Disease: Kawasaki Disease, Rheumatic Fever & Heart Failure
7 Chapter 7: Pediatric Neurological & Neuromuscular Disorders
7.1 Pediatric Seizure Disorders: Febrile Seizures, Epilepsy & Status Epilepticus 7.2 Central Nervous System Infections & Increased Intracranial Pressure 7.3 Structural Anomalies & Neuromuscular Disorders: Hydrocephalus, VP Shunts, Spina Bifida & Cerebral Palsy
8 Chapter 8: Pediatric Gastrointestinal & Hepatic Conditions
8.1 Acute Surgical Conditions: Pyloric Stenosis, Intussusception & Appendicitis 8.2 Congenital & Structural GI Anomalies: Cleft Lip/Palate, TEF & Hirschsprung Disease 8.3 Chronic GI & Malabsorption: Pediatric GERD, Celiac Disease & Inflammatory Bowel Disease
9 Chapter 9: Pediatric Renal & Genitourinary Conditions
9.1 Pediatric Urinary Tract Infections, Vesicoureteral Reflux & Enuresis 9.2 Glomerular Disorders: Minimal Change Nephrotic Syndrome & Acute Post-Streptococcal Glomerulonephritis 9.3 Hemolytic Uremic Syndrome, Acute Kidney Injury & Structural Genital Anomalies
10 Chapter 10: Pediatric Hematologic & Oncologic Conditions
10.1 Pediatric Anemias & Sickle Cell Disease Crises 10.2 Pediatric Bleeding Disorders: Hemophilia A/B & Immune Thrombocytopenia 10.3 Pediatric Leukemias, Solid Tumors & Oncologic Emergencies
11 Chapter 11: Pediatric Endocrine & Inborn Metabolic Disorders
11.1 Pediatric Type 1 Diabetes Mellitus & Diabetic Ketoacidosis Protocols 11.2 Pediatric Thyroid, Adrenal & Growth Hormone Disorders 11.3 Inborn Errors of Metabolism & Pubertal Disorders: PKU, Galactosemia & Precocious Puberty
12 Chapter 12: Pediatric Musculoskeletal, Integumentary & Infectious Disorders
12.1 Pediatric Orthopedics: Developmental Dysplasia of the Hip, Clubfoot, Scoliosis & Fractures 12.2 Pediatric Burns, Atopic Dermatitis & Dermatologic Conditions 12.3 Viral Exanthems, Communicable Diseases & Pediatric Sepsis Management
13 Chapter 13: Pediatric Pharmacology, Safe Dosage & Immunizations
13.1 Pediatric Pharmacokinetics, Weight-Based Calculations & Safe Dosing Limits 13.2 High-Alert Pediatric Medications, IV Infusion Safety & Vascular Access 13.3 CDC Childhood Immunization Schedules, Vaccine Safety & Catch-Up Guidelines
14 Chapter 14: Family-Centered Care, Psychosocial Health & Injury Prevention
14.1 Family-Centered Care Principles, Hospitalization Stress & Separation Anxiety 14.2 Developmentally Appropriate Procedural Preparation & Non-Pharmacological Comfort 14.3 Anticipatory Guidance, Car Seat Safety, Drowning & Poisoning Prevention
15 Chapter 15: Professional Role, Ethics, Legal Standards & Advocacy
15.1 Informed Consent, Minor Assent & Adolescent Confidentiality Rights 15.2 Mandatory Reporting: Identifying Child Abuse, Neglect & Human Trafficking 15.3 Evidence-Based Practice, Pediatric Quality Metrics & Interprofessional Collaboration
16 Chapter 16: Medication Reconciliation, Complementary Care & Interactions
16.1 Medication, Allergy & Treatment Reconciliation 16.2 Complementary Products & Treatment Interactions
17 Chapter 17: Individualized Assessment, Diversity & Psychosocial Safety
17.1 Culture, Resources, Religion & Individualized Care 17.2 Psychosocial Screening & Immediate Mental Health Safety
18 Chapter 18: Individualized Planning, Coordination & Family Teaching
18.1 Measurable Outcomes, Coordination & Delegation 18.2 Teach-Back, Return Demonstration & Learning Evaluation
19 Chapter 19: Patient Safety, Chronic Care & Outcome Evaluation
19.1 Withdrawal, Elopement, De-escalation & Risk Reduction 19.2 Chronic Care, Healthy Weight & Response Evaluation
12.3 Viral Exanthems, Communicable Diseases & Pediatric Sepsis Management
Key Takeaways Explain This Topic AI
Roseola typically produces a rash as the preceding fever resolves; the clinical pattern still requires assessment for other causes.
Parvovirus B19 can cause transient aplastic crisis in children with chronic hemolytic anemia.
Current pediatric sepsis definitions emphasize organ dysfunction; SIRS alone is not the current diagnostic definition.
Septic shock requires urgent treatment and reassessment; fluid volume and vasoactive choice depend on the clinical setting and response.
New crackles, worsening breathing, or hepatomegaly during resuscitation require immediate assessment for fluid overload.
Last updated: October 2026
Viral Exanthems, Communicable Diseases & Pediatric Sepsis Management
Core Clinical Focus: Febrile pediatric illnesses present a diagnostic spectrum ranging from self-limiting viral eruptions to catastrophic, life-threatening septic shock. Pediatric nurses must rapidly distinguish between contagious viral and bacterial exanthems, enforce strict transmission-based precautions, and identify subtle physiological indicators of systemic hypoperfusion. Because pediatric cardiovascular collapse occurs precipitously following compensatory failure, immediate execution of the "Golden Hour" sepsis bundle is life-saving.
1. Differential Diagnosis of Pediatric Exanthems
Pediatric exanthems often present with fever and cutaneous eruptions, but subtle variations in prodromal symptoms, enanthem morphology, rash progression, and transmission dynamics delineate individual pathologies.
Comprehensive Comparative Reference
Disease & Pathogen Transmission & Precautions Incubation & Prodrome Enanthem & Characteristic Signs Exanthem Characteristics & Distribution Clinical Course & Management
Measles (Rubeola) ( Paramyxovirus ) Airborne (aerosol droplets remain infective in air up to 2 hours) 7–14 days. High fever (up to 104°–105°F [40°C]), malaise, and the 3 Cs: Cough, Coryza, Conjunctivitis (with photophobia). Koplik Spots: Small (1–2 mm), irregular, bluish-white granular spots on an erythematous base on the buccal mucosa opposite the second molars, appearing 24–48 hours before the exanthem. Deep red, maculopapular, confluent rash starting at the hairline and behind the ears, spreading cephalocaudally over 3 days down the face, trunk, and extremities. Fades in the same order with brownish staining and fine desquamation. • Airborne isolation in negative-pressure room. • Vitamin A: Clinician-supervised age-specific dosing may be used. CDC lists 50,000 IU for infants under 6 months, 100,000 IU for 6–11 months, and 200,000 IU from 12 months, once daily for 2 days; do not use the older-child dose for a young infant. • Complications: Otitis media, severe pneumonia (most common fatal complication), acute encephalitis, subacute sclerosing panencephalitis (SSPE).
Varicella (Chickenpox) ( Varicella-Zoster Virus [VZV] ) Airborne & Contact (direct contact with vesicle fluid or inhalation of respiratory secretions) 10–21 days. Low-grade fever, malaise, headache, anorexia 24–48 hours prior to rash. Painful, shallow mucosal erosions on the palate and pharynx. Pruritic, polymorphic lesions present in all stages of development simultaneously : macules → papules → clear vesicles on an erythematous base ( "dewdrops on a rose petal" ) → pustules → umbilicated crusted scabs. Centripetal spread (trunk/scalp to limbs). • Airborne + Contact precautions until ALL lesions have completely crusted and dried (typically 6–7 days). • Antipyretics: Acetaminophen (NEVER aspirin due to Reye syndrome risk). • VariZIG within 10 days of exposure for high-risk neonates and immunocompromised patients.
Erythema Infectiosum (Fifth Disease) ( Parvovirus B19 ) Respiratory Droplet & transplacental transmission 4–14 days. Mild, non-specific low-grade fever, malaise, headache, and rhinorrhea. None characteristic. • Stage 1: Sudden bright, fiery red erythema on cheeks ( "slapped cheek" appearance) with circumoral pallor. • Stage 2: 1–4 days later, pink maculopapular rash appears on trunk and extremities, fading into a classic lacy, reticular (net-like) appearance. • Stage 3: Rash waxes and wanes for 1–3 weeks with sun exposure, heat, or exercise. • Contagious Period: Highly contagious BEFORE rash emerges; in an otherwise healthy child, infectiousness usually falls markedly by the rash phase; aplastic crisis or immune compromise can prolong infectiousness and may attend school/daycare. • High-Risk Warnings: (1) Sickle cell / spherocytosis: Triggers acute aplastic crisis (cessation of erythropoiesis). (2) Pregnancy: Maternal infection risks fetal hydrops, profound fetal anemia, and intrauterine demise.
Roseola Infantum (Sixth Disease) ( Human Herpesvirus 6 [HHV-6] ) Respiratory Secretions (salivary droplets) 9–10 days. Predominantly infants aged 6–15 months. Sudden onset of sustained high fever (103°–105°F [39.5°–40.5°C]) lasting 3–5 days in an otherwise alert and playful infant. Nagayama spots (erythematous papules on soft palate/uvula in ~30%). Hallmark: Fever breaks abruptly (defervescence), followed immediately within hours by a discrete, rose-pink maculopapular rash that originates on the trunk and neck, spreading minimally to face and limbs. Non-pruritic, blanches with pressure, resolves within 24–48 hours without desquamation. High risk of febrile seizures during rapid temperature spike. Management is supportive: hydration, antipyretics for comfort. Child is generally not contagious after fever breaks.
Scarlet Fever (Scarlatina) ( Group A Beta-Hemolytic Streptococcus [GABHS] ) Respiratory Droplet & direct contact 2–5 days. Acute onset of sore throat, fever, chills, headache, vomiting, and abdominal pain. Pharyngeal erythema with tonsillar exudates, palatal petechiae. • Strawberry Tongue: Starts as white strawberry tongue (thick white coat with prominent red papillae), sloughs by day 4 to 5 into red strawberry tongue (denuded beefy red with hyperplastic papillae). Diffuse, erythematous, punctate, pinpoint papules that blanch on pressure, imparting a coarse "sandpaper" texture. Confluent on neck and torso. • Pastia Lines: Accentuated, non-blanching pink-red transverse lines in skin flexures (antecubital, axillary, inguinal folds). Fine sheet-like desquamation of hands/feet occurs 1–3 weeks later. • Treatment: Oral Penicillin V or Amoxicillin for 10 days (erythromycin/azithromycin if allergic) to eradicate carrier state and prevent Acute Rheumatic Fever . • Child may return to school after 24 hours of therapeutic antibiotic therapy.
2. Recognize sepsis through organ dysfunction and trends
Sepsis is infection associated with life-threatening organ dysfunction. Older SIRS criteria describe inflammation but do not establish the current pediatric sepsis definition. The 2024 Phoenix criteria identify sepsis using suspected infection and a score of at least two points across respiratory, cardiovascular, coagulation, and neurologic dysfunction; septic shock additionally requires cardiovascular dysfunction. The score is not an early screening rule that must become positive before treatment begins. A child with concerning trends needs clinical assessment and escalation even while investigations are pending.
Assess appearance, responsiveness, work of breathing, pulse quality, skin perfusion, capillary refill, urine output, blood pressure, and change from baseline. Fever is not required: hypothermia can accompany serious infection. A normal blood pressure does not exclude poor perfusion. Conversely, an abnormal heart rate alone does not prove sepsis; pain, fever, dehydration, medication, and other causes require evaluation.
Initial nursing actions and repeated evaluation
Activate the institutional sepsis pathway and obtain the appropriate level of clinical support. Address airway and breathing, establish the indicated access, and arrange ordered investigations and treatment. Record recognition time, assessment findings, medications, fluid volumes, and reassessment. Clarify the child's weight in kilograms and verify concentrations and pump settings during emergency medication preparation. Caregiver concerns and a change from usual interaction may be early warning information.
Clinical question Assessment focus Result that changes the plan
Is perfusion improving? Pulses, refill, mental status, urine output, pressure trends Persistent or worsening findings require escalation
Is fluid being tolerated? Breathing, lung findings, liver size, cumulative balance New overload signs require stopping further boluses and review
Is respiratory support adequate? Air movement, effort, alertness, prescribed oxygen target Fatigue or hypoventilation requires immediate support
Has treatment reached the patient? Access, line patency, pump, ordered dose An infiltrated line or delayed drug must be addressed promptly
Current treatment principles
The 2026 Surviving Sepsis Campaign distinguishes suspected shock from probable sepsis without shock. Antibiotics should begin as soon as possible, ideally within one hour for suspected septic shock; probable sepsis without shock permits rapid evaluation with treatment ideally within three hours if concern is substantiated. Obtain cultures first only when this does not substantially delay treatment. Follow the clinician's empiric regimen, then review culture and susceptibility results for narrowing.
Where intensive care is available, fluid resuscitation uses reassessed 10–20 mL/kg aliquots, potentially up to 40–60 mL/kg in the first hour. This is not a mandatory volume for every child. Stop additional boluses when overload appears. Resource setting, hypotension, cardiac disease, and individual response alter the approach. The 2026 guideline does not establish one universally preferred first-line choice between epinephrine and norepinephrine; the critical-care team selects and titrates therapy. Peripheral access may be used under protocol rather than delaying treatment for a central line.
Avoid turning a phenotype into a prescription
Cool skin, weak pulses, and prolonged refill may be described as cold perfusion findings; warm skin and bounding pulses may suggest a different hemodynamic pattern. These observations can guide further assessment but do not accurately establish cardiac output or vascular resistance by themselves. Do not select a vasoactive drug solely from a cold-versus-warm label. Integrate the full examination, response to treatment, monitoring, and specialist assessment.
Hydrocortisone is not a routine automatic next step for every child with sepsis. Suspected or documented adrenal insufficiency requires appropriate stress-dose treatment; other refractory cases need specialist judgment and the current pathway. The nurse verifies the indication and monitors response rather than treating an old fixed sequence as universal. Similarly, oxygen and ventilation goals depend on the phase of resuscitation and the individual condition.
Evaluate beyond the first intervention
A child who becomes quieter after repeated fluid boluses may be improving, tiring, or developing overload. Reassess rather than interpreting quietness as reassurance. New crackles, increased breathing effort, hepatomegaly, worsening alertness, or poor urine output can change the plan. Communicate what was given, the cumulative amount, and the observed effect. Continued task completion without checking response can conceal deterioration.
After stabilization, evaluate fluid balance, device necessity, medication effects, nutrition, mobility, family understanding, and new functional problems. A child recovering from sepsis may need coordinated follow-up for physical, cognitive, emotional, or school-related changes. Explain warning signs and whom the family should contact. A discharge note that only states infection resolved misses the possibility of ongoing effects and unresolved family needs.
- Source checks
- SCCM 2026 pediatric sepsis recommendations
- 2024 pediatric sepsis consensus criteria
- CDC measles clinical overview and vitamin A doses
Checked October 18, 2026. The examples teach nursing assessment and evaluation; administration follows the applicable clinical orders and pathway.